Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1956 1
1961 1
1973 2
1974 1
1975 5
1976 5
1977 1
1978 1
1979 4
1981 3
1982 2
1983 3
1984 4
1985 5
1987 4
1988 3
1990 3
1991 1
1992 3
1993 2
1994 2
1995 2
1996 3
1997 2
1998 5
1999 2
2000 4
2001 12
2002 3
2003 3
2004 8
2005 4
2006 3
2007 7
2008 8
2009 8
2010 15
2011 7
2012 5
2013 6
2014 7
2015 7
2016 2
2017 2
2018 1
2019 5
2020 6
2021 7
Text availability
Article attribute
Article type
Publication date

Search Results

192 results
Results by year
Filters applied: . Clear all
Page 1
Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial.
Gottlieb RL, Nirula A, Chen P, Boscia J, Heller B, Morris J, Huhn G, Cardona J, Mocherla B, Stosor V, Shawa I, Kumar P, Adams AC, Van Naarden J, Custer KL, Durante M, Oakley G, Schade AE, Holzer TR, Ebert PJ, Higgs RE, Kallewaard NL, Sabo J, Patel DR, Klekotka P, Shen L, Skovronsky DM. Gottlieb RL, et al. Among authors: higgs re. JAMA. 2021 Feb 16;325(7):632-644. doi: 10.1001/jama.2021.0202. JAMA. 2021. PMID: 33475701 Free PMC article. Clinical Trial.
Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients.
Stebbing J, Krishnan V, de Bono S, Ottaviani S, Casalini G, Richardson PJ, Monteil V, Lauschke VM, Mirazimi A, Youhanna S, Tan YJ, Baldanti F, Sarasini A, Terres JAR, Nickoloff BJ, Higgs RE, Rocha G, Byers NL, Schlichting DE, Nirula A, Cardoso A, Corbellino M; Sacco Baricitinib Study Group. Stebbing J, et al. Among authors: higgs re. EMBO Mol Med. 2020 Aug 7;12(8):e12697. doi: 10.15252/emmm.202012697. Epub 2020 Jun 24. EMBO Mol Med. 2020. PMID: 32473600 Free PMC article.
LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection.
Jones BE, Brown-Augsburger PL, Corbett KS, Westendorf K, Davies J, Cujec TP, Wiethoff CM, Blackbourne JL, Heinz BA, Foster D, Higgs RE, Balasubramaniam D, Wang L, Bidshahri R, Kraft L, Hwang Y, Žentelis S, Jepson KR, Goya R, Smith MA, Collins DW, Hinshaw SJ, Tycho SA, Pellacani D, Xiang P, Muthuraman K, Sobhanifar S, Piper MH, Triana FJ, Hendle J, Pustilnik A, Adams AC, Berens SJ, Baric RS, Martinez DR, Cross RW, Geisbert TW, Borisevich V, Abiona O, Belli HM, de Vries M, Mohamed A, Dittmann M, Samanovic M, Mulligan MJ, Goldsmith JA, Hsieh CL, Johnson NV, Wrapp D, McLellan JS, Barnhart BC, Graham BS, Mascola JR, Hansen CL, Falconer E. Jones BE, et al. Among authors: higgs re. bioRxiv. 2020 Oct 1:2020.09.30.318972. doi: 10.1101/2020.09.30.318972. Preprint. bioRxiv. 2020. PMID: 33024963 Free PMC article. Updated.
Characterization of the cytokine storm reflects hyperinflammatory endothelial dysfunction in COVID-19.
Sims JT, Krishnan V, Chang CY, Engle SM, Casalini G, Rodgers GH, Bivi N, Nickoloff BJ, Konrad RJ, de Bono S, Higgs RE, Benschop RJ, Ottaviani S, Cardoso A, Nirula A, Corbellino M, Stebbing J. Sims JT, et al. Among authors: higgs re. J Allergy Clin Immunol. 2021 Jan;147(1):107-111. doi: 10.1016/j.jaci.2020.08.031. Epub 2020 Sep 10. J Allergy Clin Immunol. 2021. PMID: 32920092 Free PMC article.
Gene Expression and Pharmacodynamic Changes in 1,760 Systemic Lupus Erythematosus Patients From Two Phase III Trials of BAFF Blockade With Tabalumab.
Hoffman RW, Merrill JT, Alarcón-Riquelme MM, Petri M, Dow ER, Nantz E, Nisenbaum LK, Schroeder KM, Komocsar WJ, Perumal NB, Linnik MD, Airey DC, Liu Y, Rocha GV, Higgs RE. Hoffman RW, et al. Among authors: higgs re. Arthritis Rheumatol. 2017 Mar;69(3):643-654. doi: 10.1002/art.39950. Arthritis Rheumatol. 2017. PMID: 27723281 Free PMC article. Clinical Trial.
Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathways.
Dörner T, Tanaka Y, Petri MA, Smolen JS, Wallace DJ, Dow ER, Higgs RE, Rocha G, Crowe B, Benschop RJ, Byers NL, Silk ME, de Bono S, Fantini D, Hoffman RW. Dörner T, et al. Among authors: higgs re. Lupus Sci Med. 2020 Oct;7(1):e000424. doi: 10.1136/lupus-2020-000424. Lupus Sci Med. 2020. PMID: 33037080 Free PMC article.
Evaluation of various static in vitro-in vivo extrapolation models for risk assessment of the CYP3A inhibition potential of an investigational drug.
Vieira ML, Kirby B, Ragueneau-Majlessi I, Galetin A, Chien JY, Einolf HJ, Fahmi OA, Fischer V, Fretland A, Grime K, Hall SD, Higgs R, Plowchalk D, Riley R, Seibert E, Skordos K, Snoeys J, Venkatakrishnan K, Waterhouse T, Obach RS, Berglund EG, Zhang L, Zhao P, Reynolds KS, Huang SM. Vieira ML, et al. Among authors: higgs r. Clin Pharmacol Ther. 2014 Feb;95(2):189-98. doi: 10.1038/clpt.2013.187. Epub 2013 Sep 18. Clin Pharmacol Ther. 2014. PMID: 24048277
Interprofessional Education for Cancer Care.
McKinlay E, White K, McChesney P, Hardie C, Higgs R, Hilder J, Gallagher P. McKinlay E, et al. Among authors: higgs r. Clin Teach. 2019 Oct;16(5):519-524. doi: 10.1111/tct.12985. Epub 2018 Dec 17. Clin Teach. 2019. PMID: 30560577
192 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page